Handelsbanken Fonder AB Has $2.21 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Handelsbanken Fonder AB lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 67.7% in the third quarter, HoldingsChannel.com reports. The firm owned 191,409 shares of the company’s stock after purchasing an additional 77,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Roivant Sciences were worth $2,209,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences in the 2nd quarter valued at $34,000. Point72 Hong Kong Ltd acquired a new stake in Roivant Sciences in the second quarter worth about $36,000. Quarry LP bought a new stake in Roivant Sciences during the 2nd quarter worth about $53,000. Acadian Asset Management LLC acquired a new position in Roivant Sciences during the 1st quarter valued at about $72,000. Finally, Fifth Third Wealth Advisors LLC bought a new position in shares of Roivant Sciences in the 2nd quarter valued at about $101,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $11.51 on Thursday. The stock’s fifty day simple moving average is $11.58 and its 200 day simple moving average is $11.15. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $8.50 billion, a PE ratio of 2.27 and a beta of 1.24. Roivant Sciences Ltd. has a 12 month low of $8.24 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same quarter in the previous year, the business posted ($0.38) EPS. Roivant Sciences’s revenue for the quarter was up 155.1% on a year-over-year basis. On average, research analysts predict that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

Insider Buying and Selling at Roivant Sciences

In related news, CAO Rakhi Kumar sold 250,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at $2,488,838.58. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the transaction, the director now directly owns 22,179,358 shares of the company’s stock, valued at $262,160,011.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the completion of the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,477,309 shares of company stock valued at $40,986,184. 4.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of recent research reports. Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Piper Sandler raised their price target on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.39.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.